Telitacicept and low-dose steroids for hard-to-treat myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new medicine called telitacicept combined with low-dose steroids for people with hard-to-treat myasthenia gravis. The goal is to see if this combination can better control symptoms that haven't improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 85 years old.
- You must have been diagnosed with myasthenia gravis and tested positive for AChR antibodies.
- Your myasthenia gravis must be considered 'refractory'—meaning standard treatments haven't worked well, or you can't tolerate them.
- You must have unstable symptoms (a score of 6 or more on the MG-ADL scale) despite taking your current medicines.
- You must not have active infections like shingles, HIV, or tuberculosis, or a thymus tumor.
- You must not be pregnant or breastfeeding, and you must not have had certain other treatments (like IVIG or plasmapheresis) in the last 2 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking two drugs one after the other—efgartigimod followed by telitacicept—is safe and effective for people with generalized myasthenia gravis. It may offer a new treatment option if standard therapy isn't enough.
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
This trial is testing a new type of cell therapy called CAR-T that targets two proteins (CD19 and BCMA) on certain immune cells. It aims to help people with severe myasthenia gravis that has not improved with standard treatments.
This trial tests an experimental cell therapy (UCAR T-cells) that targets two markers on immune cells to treat myasthenia gravis that hasn't improved with standard treatments. It aims to reduce symptoms and improve daily functioning.
This trial tests a new medication called Telitacicept for people with generalized myasthenia gravis (gMG). The goal is to see if it can reduce muscle weakness and improve daily function. You may be able to join if you have moderate to severe symptoms and have not had recent thymoma or other serious health issues.
This trial tests a new drug, telitacicept, for people with myasthenia gravis that only affects the eyes (ocular myasthenia gravis). The goal is to see if it can improve symptoms like droopy eyelids or double vision.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.